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Introduction: The Rho GTPase Cdc42 is overexpressed and hyperactivated in breast tumors compared to normal
breast tissue. Cdc42 regulates key processes that are critical for mammary gland morphogenesis and become
disrupted during the development, progression, and metastasis of breast cancer. However, the contribution of
Cdc42 to normal and neoplastic mammary gland development in vivo remains poorly understood. We were
therefore interested in investigating the effects of Cdc42 overexpression on mammary gland morphogenesis as a
first step toward understanding how its overexpression may contribute to mammary tumorigenesis.
Methods: We developed a tetracycline-regulatable Cdc42 overexpression mouse model in which Cdc42 can be
inducibly overexpressed in the developing mammary gland. The effects of Cdc42 overexpression during postnatal
mammary gland development were investigated using in vivo and in vitro approaches, including morphometric
analysis of wholemounted mammary glands, quantification of histological markers, and primary mammary epithelial
cell (MEC) functional and biochemical assays.
Results: Analysis of Cdc42-overexpressing mammary glands revealed abnormal terminal end bud (TEB)
morphologies, characterized by hyperbudding and trifurcation, and increased side branching within the ductal tree.
Quantification of markers of proliferation and apoptosis suggested that these phenotypes were not due to
increased cell proliferation or survival. Rather, Cdc42 overexpressing MECs were more migratory and contractile and
formed dysmorphic, invasive acini in three-dimensional cultures. Cdc42 and RhoA activities, phosphorylated myosin
light chain, and MAPK signaling, which contribute to migration and invasion, were markedly elevated in Cdc42
overexpressing MECs. Interestingly, Cdc42 overexpressing mammary glands displayed several features associated
with altered epithelial-stromal interactions, which are known to regulate branching morphogenesis. These included
increased stromal thickness and collagen deposition, and stromal cells isolated from Cdc42 overexpressing
mammary glands exhibited elevated mRNA expression of extracellular matrix proteins and remodeling enzymes.
Conclusions: These data suggest that Cdc42 overexpression disrupts mammary gland branching morphogenesis
by altering Rho GTPase and MAPK signaling, leading to increased MEC contractility and migration in association
with stromal alterations. Our studies provide insight into how aberrant Cdc42 expression may contribute to
mammary tumorigenesis.* Correspondence: vargo-gogola.1@nd.edu
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Cell division cycle 42 (Cdc42) is a member of the Ras
homolog (Rho) family of small guanine nucleotide
triphophatases (GTPases) that is overexpressed and
hyperactivated in human breast invasive ductal carcin-
omas [1-3]. A number of studies in other cell and tissue
types have demonstrated that Cdc42 regulates cell cycle
progression, polarity, migration, cell fate determination,
and differentiation, which are essential for mammary
gland development and become disrupted during tumor
formation [4-6]. We previously showed that Cdc42 is
required for primary mammary epithelial cell (MEC)
morphogenesis in vitro and that it regulates polarity es-
tablishment, proliferation, and survival of MECs during
acinar morphogenesis [7]. Studies investigating the im-
portance of Cdc42 during postnatal mammary gland
development in vivo are currently ongoing in our la-
boratory, and our data indicate that Cdc42 knockout
MECs are outcompeted by wild-type neighboring MECs
(Bray and Vargo-Gogola, unpublished results). Thus,
these loss-of-function studies indicate that Cdc42 is im-
portant for normal mammary gland morphogenesis
in vitro and in vivo. However, our understanding of the
mechanisms by which aberrant expression of Cdc42
disrupts mammary gland morphogenesis and facilitates
tumor formation and progression in vivo has been lim-
ited until now due to a paucity of in vivo mouse models
of Cdc42 overexpression and hyperactivation.
Postnatal mammary gland development is initiated in
mice at 3 weeks of age when rising levels of ovarian hor-
mones and local growth factors stimulate MEC prolifer-
ation and motility within terminal end buds (TEBs). The
concerted action of MEC proliferation and motility
drives TEB invasion and branching into the mammary
fat pad, giving rise to an arborized ductal tree [8]. Mam-
mary gland branching morphogenesis also requires re-
iterative interactions between the epithelial and stromal
compartments, and both secreted factors and mechan-
ical signals between the two compartments contribute to
branch formation and patterning [9-11].
Rho family GTPases function within epithelia to inte-
grate and transduce bidirectional soluble and mechanical
signals between the epithelial and stromal compartments
[12]. Studies indicate that Rho signaling coordinates cell
proliferation and motility with changes in cell shape and
intracellular contractility that are important for out-
growth and patterning of the branched mammary ductal
tree. For example, real-time imaging studies using an
in vitro model of mammary gland branching have re-
vealed that Ras-related C3 botulinum toxin substrate 1
(Rac) and actomyosin contractility are required for mam-
mary gland branch formation, whereas Rho-associated
coiled-coil containing protein kinase (ROCK) functions to
suppress hyperbranching and promote reorganization ofthe bilayered mammary epithelium [9,13]. Although Rac
and ROCK have been implicated in mammary gland
branching morphogenesis, the contribution of Cdc42 is
not well understood.
To investigate the effects of Cdc42 overexpression during
normal and neoplastic mammary gland development in vivo
we developed a Cdc42 conditional overexpression mouse
model and examined the effects of Cdc42 overexpression
during postnatal mammary gland morphogenesis. We
show that Cdc42 overexpression disrupts TEB morpho-
genesis and induces hyperbranching. Intriguingly, Cdc42
overexpression does not impact cell cycle progression to
drive increased branching. Rather, it enhances MEC con-
tractility and migration potentially by activating mitogen-
activated protein kinase (MAPK) signaling. Our studies
also suggest that Cdc42 overexpression in the mammary
epithelium alters epithelial-stromal interactions, leading to
stromal alterations that likely contribute to the epithelial
phenotypes.
Methods
Mouse husbandry and care
Mice were housed in the University of Notre Dame
Freimann Life Science Center. All studies were approved
by the Institutional Animal Care and Use Committee at
the University of Notre Dame and Indiana University
School of Medicine (Protocol Number 14-015) and were
conducted in accordance with the guidelines of the US
Public Health Service Policy for Humane Care and Use of
Laboratory Animals. All efforts were made to minimize
suffering of the mice. Mice were fed a conventional diet
or doxycyline (dox) containing chow ad libitum and
were maintained at 21 to 22°C with a 12-hour light and
12-hour dark cycle. To induce transgene expression or
control for any effects of dox, bitransgenic and control
female mice were fed dox-containing chow (2 g/kg)
(Bio-Serv Inc, Frenchtown, NJ, USA, S3893) for the speci-
fied number of weeks beginning at 4.5 weeks of age.
Transgenic mice
To generate the tetracycline (tet)-regulatable Cdc42 trans-
genic mouse model we created the following construct.
The approximately 600 bp wild-type human Cdc42 cDNA
was subcloned from the pCMV-Sport6 vector (Thermo
Scientific Open BioSystems, Waltham, MA, USA) using
PCR. Primers used to create and subclone the insert were
as follows: Forward-5′-CCG GAA TTC ATG TAC CCA
TAC GAT GTT CCA GAT TAC GCT CAG ACA ATT
AAG TGT GTT GTT GTG GGC GAT G-3′ and reverse-
5′-CCG GAA TTC GAT GTT CAT AGC AGC ACA
CAC CTG-3′. The forward primer contained an EcoRI
site and an ATG start site. The reverse primer contained
an EcoRI restriction site. The PCR product was gel puri-
fied and digested with EcoRI. The Cdc42 insert was then
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IRES-luciferase vector downstream of the TetO [14].
The construct was sequenced and then tested in MCF7
Tet-On cells [15], which confirmed inducibility. A 5.2 Kb
fragment containing the TetO-Cdc42-IRES-luciferase
cassette was microinjected into the pronuclei of fertil-
ized FVB/N oocytes by the Transgenic and Knockout
Mouse Core at the Indiana University School of Medicine,
Indianapolis, IN, USA. PCR was used to identify founder
mice, which were bred with mouse mammary tumor
virus-reverse tetracycline transactivator mice (MMTV-
rtTA) [16] already in use in our laboratory [17]. Mice were
maintained on an inbred FVB/N background.Genotyping
Primer pairs used to genotype mice for the presence of the
MMTV-rtTA transgene were: 5′-TCC AAG GGC ATC
GGT AAA CA-3′ and 5′-GCA TCA AGT CGC TAA
AGA AG-3′. Reaction conditions were 94°C for 3 min,
followed by 30 cycles of 94°C for 30 s, 60°C for 45 s, and
72°C for 45 s followed by one cycle of 72°C for 5 min.
Glycerol, 3 μl of a 50% solution, was added as part of a
25 μl total reaction volume to enhance product yield.
Primer pairs used to genotype mice for the presence of
the TetO-Cdc42 transgene were: 5′-CGT CAG ATC
GCC TGG AGA CG-3′ and 5′-GAT GTT CAT AGC
AGC ACA CAC CTG CGG-3′. Reaction conditions
were 94°C for 3 min, followed by 30 cycles of 94°C for
1 min, 55°C for 30 s, and 72°C for 30 s, followed by one
cycle of 72°C for 5 min.Wholemount mammary gland preparation and
morphometric analysis
Number 4 left mammary glands were fixed immediately
after dissection in 4% PFA in PBS for 2 h while rocking on
ice. Glands were rinsed in PBS and stained in carmine
overnight with gentle rocking followed by destaining and
dehydration in a series of ethanols for 1 h each with
gentle rocking. Glands were cleared in xylenes over-
night and stored long term in methyl salicylate. A
StereoImager (Carl Zeiss, Inc, Oberkochen, Germany)
was used to image the carmine-stained glands at low mag-
nification (16×) for quantification of gland size and at high
magnification (80×) for quantification of branching, ductal
dilation, and TEB morphology. Branching was quantified
by counting the total number branch nodes found in three
4 × 106 μm2 defined areas adjacent to the sides and lead-
ing edge of the lymph node. Ductal tree area was mea-
sured using the outline measurement tool in AxioVision
4.6 software (Zeiss). Ductal dilation was quantified using
high magnification images (80×) and scoring the number
of independent dilated regions found within the ductal
tree from the back of the lymph node toward the leadingend of the fat pad. Abnormal TEBs were defined as TEBs
that were trifurcated or had multiple buds on the neck.
Histological methods and image quantification
Glands were fixed immediately after dissection in 4%
PFA in PBS for 2 h while rocking on ice, rinsed in PBS,
and stored in 70% ethanol at 4°C until paraffin embed-
ding. Five-μm sections were cut, deparaffinized in xy-
lenes, and rehydrated. Antigen retrieval was performed
by boiling the sections for 20 min in 10 mM sodium cit-
rate buffer. Sections were blocked and antibodies were
diluted in 5% BSA/Tween or M.O.M.™ block reagent and
M.O.M.™ antibody diluents (Vector Laboratories, Burlin-
game, CA, USA, BMK2202) for mouse-derived primary
antibodies. Sections were incubated with blocking buf-
fer for 1 h, with primary antibodies overnight, and sec-
ondary antibodies for 1 h. Elite ABC Reagent (Vector
Laboratories, PK7100) and DAB (Vector Laboratories,
SK-4100) were used to develop staining for immunohis-
tochemistry (IHC) and the slides were counterstained
with hematoxylin (Thermo Fisher Scientific, CS400-1D).
For immunofluorescence staining Alexa Fluor™ 488 anti-
mouse (Molecular Probes, Eugene, OR, USA, A11001),
Alexa Fluor™ 488 anti-rat (A11006), Alexa Fluor™ 555
anti-rabbit (A21428), and Texas Red™-X anti-rabbit
(T-6391) secondary antibodies were used. Masson’s Tri-
chrome staining to detect collagen was done and quanti-
fied as previously described [18]. At least five animals
per group and a minimum of three TEBs per animal
were analyzed for each experiment. Images were taken
using an AxioImager (Zeiss). Images were quantified
using the ImageJ cell counter plugin.
Bromodeoxyuridine (BrdU) injection of mice
Control and Cdc42-overexpressing mice treated with
dox-containing chow for three weeks were given intra-
peritoneal injections of 3 mg/ml BrdU (Sigma-Aldrich,
St Louis, MO, USA, B-5002) in saline at 10 μl per gram
bodyweight 2 h prior to euthanasia and dissection of the
mammary glands. The glands were fixed and stained as
described above.
Organoid and fibroblast isolation for luciferase assays,
GLISA, and qRT-PCR
Four-and-a-half-week-old Cdc42-overexpressing and con-
trol mice were treated with the dox diet for 1 week prior to
euthanasia and mammary gland dissection. The 2, 3, and 4
mammary gland pairs were dissected, and lymph nodes
were removed from the number 4 glands. Organoids
and fibroblasts were isolated as previously described
[18]. Briefly, the glands were manually minced and
incubated in DMEM/F-12 (Thermo Fisher Scientific,
SH30272) with 2 mg/ml collagenase A (Roche, Geneva,
Switzerland, 10103578001), 100 units/ml hyaluronidase
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(Invitrogen, Carlsbad, CA, USA, 15240-062) for 1 h at
37°C with 200 rpm rotation at a 45° angle. The tissues
were shaken manually at 30 min and 60 min during the
digestion to aid in breaking apart the tissues. The cells
were washed with DMEM/F-12 and centrifuged twice
at 450 g for 10 min. The cells were incubated at room
temperature for 3 min with manual shaking in DMEM/
F-12 with 2 units/ml DNase I (Sigma-Aldrich, D2463)
and centrifuged at 450 g for 10 min. Differential centri-
fugation was used to separate fibroblasts from organoids,
which consisted of pulse centrifugation to 450 g with the
supernatant from the first spin containing the fibroblasts.
Fibroblasts and organoids for luciferase assays were imme-
diately frozen. Fibroblasts for qRT-PCR were frozen in
Trizol (Invitrogen, 15596-018) for RNA isolation.
Single mammary epithelial cell isolation
Primary MECs used in in vitro assays were isolated
from the 2, 3, and 4 mammary glands from mice
treated for 1 week with dox. Initial steps for single cell
isolation were identical to those used for organoid iso-
lation as described above. Cells were washed in PBS
and then digested in 0.05% trypsin + EDTA in PBS for
5 min at 37°C with 200 rpm rotation. An equivalent
volume of wash buffer was added and cells were tritu-
rated at least 50 times with a p1000 pipette. Cells were
spun at 600 g for 3 min. Cells were counted and used
immediately for in vitro experiments or were frozen in
90% FBS + 10% DMSO freezing media and later thawed
for some of the in vitro experiments.
Luciferase assays
Lysates used for luciferase assay were prepped from pulver-
ized frozen whole glands, organoids, or fibroblasts in pas-
sive lysis buffer (Promega, Madison, WI, USA, E1941).
After a 10-min incubation on ice, the lysates were
centrifuged at 13,000 rpm at 4°C for 10 min to remove
debris. Lysates were allowed to warm to room temperature
before luciferase substrate (Promega, E148) was added. A
GloMax 20/20 Luminometer (Promega) was used to read
luciferase activity. Values were normalized to total protein
determined by BCA assay (Pierce, Rockford, IL, USA,
23225).
Western blot analysis
Lysates used for western blot analysis were derived from
whole glands snap frozen in liquid nitrogen immediately
after dissection. Frozen glands were pulverized with a
mortar and pestle followed by lysis in ice-cold RIPA buffer
plus protease and phosphatase inhibitors (Pierce, 78440)
for 10 min on ice. The lysates were then cleared by centri-
fugation at 10,000 rpm for 10 min at 4°C. BCA assay was
used to determine lysate protein concentrations. Lysateswere electrophoresed on 10% SDS-polyacrylamide gels
and transferred onto PVDF membranes. Five percent milk
in TBST was used for blocking and primary antibodies
were diluted in 5% milk/TBST and incubated with the
membrane for 2 h or overnight. Blots were probed with
secondary HRP-conjugated antibodies (Jackson Immuno-
logicals, West Grove, PA, USA) for 1 h. Phosphorylated
primary antibodies were diluted in 5% BSA in TBST. Blots
were developed using a GE Healthcare (Little Chalfont,
UK) ImageQuant and ImageJ was used to calculate densi-
tometry values.
Antibody concentrations
The following antibodies were used at the indicated di-
lutions for the specified applications. Western analysis:
β-actin 1:5000 (Sigma-Aldrich, A5441); Cdc42 1:1000
(BD Transduction Laboratories, San Jose, CA, USA,
610929); phosphorylated MLC ser19 1:1000 (Cell Sig-
naling, Beverly, MA, USA, 3671); phosphorylated ERK
1:1000 (Cell Signaling, 4370); total Erk 1:1000 (Cell Sig-
naling, 4695); phosphorylated p38 1:1000 (Cell Signal-
ing, 4511); β-tubulin (Sigma-Aldrich, T5201). IHC/IF:
Ki67 1:5000 (Abcam, Cambridge, UK, ab15580); BrdU
1:1000 (Thermo Fisher Scientific, MA3-071); CC3 1:1000
(Cell Signaling, 9661); phosphorylated histone-H3 1:5000
(Merck Millipore, Darmstadt, Germany, 06-570); F4/80
1:50, no antigen retrieval (Invitrogen, MF48000); phos-
phorylated ERM 1:1000 (Cell Signaling, 3141); E-cadherin
1:250 (BD Transduction, 610181); K14 1:400 (Covance,
Leeds, UK, PRB-155P); K8 1:250 (Developmental Studies
Hybridoma Bank, TROMA-I). The K8 monoclonal anti-
body developed by Philippe Brulet and Rolf Kemler was
obtained from the Developmental Studies Hybridoma
Bank developed under the auspices of the NICHD and
maintained by The University of Iowa, Department of
Biology, Iowa City, IA, USA, 52242.
RNA isolation and qRT-PCR
RNA was isolated from control and Cdc42-associated
fibroblasts from three mice per genotype pooled using
Trizol and an RNeasy RNA purification column (Qiagen,
Valencia, CA, USA, 91355) according to manufacturer’s
recommendations. One μg of RNA was converted to
cDNA using the RT2 First Strand Kit (Qiagen, 330401)
and amplified using RT2 Profiler PCR Array Mouse
Extracellular Matrix and Adhesion Molecules (PAMM-
013A) per manufacturer’s instructions. Data were ana-
lyzed using the web-based software RT2 Profiler PCR
Array Data Analysis from SABiosciences (Frederick, MD,
USA). To validate gene expression changes identified by
the array, cDNA was amplified using RT2 SYBR Green
qPCR Master Mix (Qiagen, 330522), the StepOnePlus
Real-Time PCR System (Applied Biosystems, Foster City,
CA, USA), and the following primers: Col1a1 primers:
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CGT CTC ACC ATT GGG G-3′; Fn1 primers: 5′-TTC
AAG TGT GAT CCC CAT GAA G-3′ and 5′-CAG GTC
TAC GGC AGT TGT CA-3′; Mmp2 primers: 5′-ACC
TGA ACA CTT TCT ATG GCT G-3′ and 5′-CTT CCG
CAT GGT CTC GAT G-3′; Mmp3 primers: 5′-ACA
TGG AGA CTT TGT CCC TTT TG-3′ and 5′-TTG
GCT GAG TGG TAG AGT CCC-3′; Mmp9 primers: 5′-
CTG GAC AGC CAG ACA CTA AAG-3′ and 5′-CTC
GCG GCA AGT CTT CAG AG-3′; and Gapdh primers:
5′-CCA ATG TGT CCG TCG TGG ATC-3′ and 5′-GTT
GAA GTC GCA GGA GAC AAC-3′. The reaction was
setup in triplicate and conditions were as follows: 95°C for
10 min then 40 cycles of 95°C for 15 s and 60°C for 1 min
followed by a melting curve. Col1a1, Fn1, Mmp2, Mmp3,
and Mmp9 mRNA levels were normalized to Gapdh
mRNA levels and the data was analyzed using compara-
tive CT.Cdc42, RhoA, and Rac1 activity assays on isolated
organoids
GLISA Cdc42 Activated Assay Biochem Kit (Cytoskeleton,
Denver, CO, USA, BK127), GLISA RhoA Activation Assay
Biochem Kit (Cytoskeleton, BK121) and Rac1 Activation
Assay Biochem Kit (Cytoskeleton, BK126) were used to
measure levels of activated Cdc42, RhoA, and Rac1
according to the manufacturer’s instructions. Mammary
organoid lysates were prepared using the kit lysis buffer.
Organoids isolated from two to five mice were pooled per
group after 1 week and 3 weeks of dox treatment and the
assays were run in triplicate. All lysates were prepared
within 10 min prior to snap freezing.Contraction assays
Primary MEC contractility was analyzed using the Cell
Contraction Assay (Cell Biolabs, Inc., San Diego, CA, USA,
CBA201) according to the manufacturer’s instructions.
Growth media (MEGM BulletKit, Lonza, Walkersville,
MD, USA, CC-3150) with 2 μg/ml dox was added once the
gels solidified and changed when the gels were released
and after each time point measurement. ROCK inhibitor,
25 μM Y27632 (Tocris Bioscience, Bristol, UK, 1254), or
an equal volume of vehicle was added when the gels were
released. Quantification of gel contraction was done using
images of the gels taken immediately after their release and
after 24 and 48 h post release to measure the difference in
gel area from time of release. Imaging and quantification
was done with a Zeiss Axioimager A1 epifluorescence
microscope. Individual assays were conducted in duplicate
or triplicate and averaged. Data without inhibitor are repre-
sentative of four independent experiments and data with
the ROCK inhibitor are representative of two independent
experiments.In vitro migration assays
Cryopreserved primary MECs were used for these
studies. Approximately 500,000 MECs were plated onto
a 6-cm dish and allowed to adhere to the plate and form
characteristic epithelial cobblestone patches in MEGM
Bullet Kit Media + dox. The media was replaced with
serum-free F12 + dox and the cells were serum starved
for 24 h. The cells were washed with PBS, trypsinized
with 0.05% trypsin for 15 min and removed. Cells were
then spun at 600 g for 3 min and resuspended in F12
media + dox and plated onto 8 μm-pore transwell filters
(BD Transduction Laboratories) into 24-well plates
(75,000 cells per well). Eight hundred μl of serum
containing MEGM media was added to each well below
the filter. The cells were allowed to migrate through the
filter for 24 h at which time the upper surface of the fil-
ter was scraped twice with a cotton swab and media was
suctioned off to remove any cells that did not migrate
through the filter. The filters were then fixed in 4% PFA
for 20 min and permeabilized for 10 min with 0.05%
Triton-X 100 (Thermo Fisher Scientific, BP151). The fil-
ters were then removed from the well, transferred to a
glass slide, and mounted with Vectashield + DAPI (Vector
Laboratories, H-1200). A minimum of nine, 200× fields
per filter were quantified and the total number of mi-
grated cells was recorded per experiment. The fold
changes of total migrated cells between control and
Cdc42-overexpressing MECs were averaged from four
independent experiments. Seven control mice and 11
Cdc42 overexpressing mice are represented in the data.
Three-dimensional (3D) culture assays
Primary MECs were isolated and plated on tissue culture
plastic plates. MECs from at least three mice were
pooled per group for each experiment. Plates were
treated with 2% Matrigel containing MEGM media for
at least 1 h at 37°C prior to plating of the cells. Cells
were allowed to adhere to the plate and form character-
istic epithelial cobblestone patches. After 48 to 72 h, the
cells were washed with PBS, trypsinized with 0.05% tryp-
sin for 15 min and removed. Cells were then spun at
600 g for 3 min and resuspended at 15,000 or 30,000
cells per well in 40 μl Matrigel per well of an 8-well
chamber slide. The gel was allowed to solidify for 20
min at 37°C and 400 μl of warm MEGM + 2% Matrigel +
2 μg/ml dox was added to each well. The media was re-
placed every 3 days and the cultures were analyzed after
5 days using immunostaining and a Zeiss LSM 7 con-
focal microscope. Entire wells were quantified for each
experiment. Invasive acini were defined as structures
made up of five or more cells that had an invasive pro-
trusion or at least one cell actively migrating away from
the acinus. Data represent the average fold change be-
tween control and Cdc42-overexpressing MECs in three
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fined as acini with nonspherical morphologies with or
without invasive protrusions or cells migrating away
from the acinus. Data represent the average fold change
between control and Cdc42 overexpressing acini in a
total of three wells per group from three independent
experiments.
For the spindle orientation three-dimensional culture
assays, cryopreserved primary MECs were used and
plated as described above. After 48 h, the cultures were
fixed, immunostained with antibodies to tubulin and α6-
integrin to identify the spindle and basal surface, re-
spectively, and quantified using confocal microscopy.
Acini were defined as structures with three or more
clustered cells as previously described [7], and the first
25 acini identified with a mitotic spindle were quantified.
Data represent the percentages of structures with the
spindle parallel, perpendicular, or angled relative to the
basal surface of the forming acinus out of the total num-
ber of structures. Two independent experiments were
performed and MECs from at least four mice were
pooled per group for each experiment.
Three-dimensional culture immunofluorescence (IF)
staining
Staining was performed using methods adapted from
Debnath et al., [19]. Three-dimensional acini were fixed
with 2% or 4% PFA for 20 min at room temperature,
permeabilized with 0.5% Triton-X 100 in PBS for 10 min,
washed in 7.5 mg/ml glycine (Thermo Fisher Scientific,
G46-1) in PBS. IF buffer consisted of 7.7 mM NaN3, 0.1%
BSA, 0.2% Triton X-100, and 0.05% Tween-20 in PBS.
Invasive three-dimensional culture assay wells were
stained with Alexa Fluor™ 488 phalloidin (Molecular
Probes, Carlsbad, CA, USA, A12379) diluted 1:50 in IF
buffer for 1 h and TO-PRO3 (Molecular Probes,
T3605) diluted 1:200 in PBS for 10 to 20 min. Mitotic
spindle orientation culture wells were stained overnight
with α6-integrin (Millipore, MAB1378) diluted 1:200 in
IF buffer + 10% goat serum (Sigma-Aldrich, G9023)
and α-tubulin (Abcam, Ab1825) diluted 1:400 in IF buf-
fer + 10% goat serum. Wells were stained with Alexa
Fluor™ 488 goat anti-rat (Invitrogen, A11006) and Alexa
Fluor™ 555 goat anti-rabbit (Molecular Probes, A21428)
secondary antibodies diluted 1:200 in IF buffer + 10%
goat serum for 1 h and TO-PRO3 diluted 1:200 in PBS
for 10 to 20 min. All slides were mounted with 4 μl
Vectashield + DAPI per well with coverslips and
allowed to dry in the dark for 24 to 72 h before sealing
coverslips with nail polish and imaging.
Flow cytometry analysis
Single MECs isolated as described above were suspended
in 1 ml of PBS and fixed by adding 2.5 ml of 100%ethanol. Ethanol was added 500 μl at a time while gently
vortexing to prevent clumping, and cells were fixed on ice
for 15 min and stored at 4°C until analysis. Cells were
pelleted by centrifugation at 600 g for 5 min and
resuspended in propidium iodide (PI) staining solution
(50 μg/ml PI; 0.1 mg/ml RNAse A; 0.05% Triton X-100)
and incubated for 30 min in a 37°C water bath. The cells
were transferred using a 26 G syringe through a cell
strainer cap of a flow tube (BD Falcon, Franklin Lakes, NJ,
USA, 352235) to break up clumps. At least 10,000 events
were analyzed using a Beckman Coulter (Brea, CA, USA)
FC500 Flow Analyzer for PI fluorescence intensity. MECs
from two to three mice were pooled for each experiment.
Data are representative of two independent experiments.
Statistical analysis
Unpaired Student’s t test was used for all statistical tests.
P values less than 0.05 were considered significant. Error
bars represent the standard error of the mean.
Results
Generation of TetO-Cdc42-overexpressing mice
To investigate the effects of Cdc42 overexpression on
the developing mammary gland we generated a regulatable
Cdc42 overexpression mouse model. In this model,
overexpression of wild-type Cdc42 is induced in the
mammary gland by feeding TetO-Cdc42/MMTV-rtTA
bitransgenic mice (referred to as Cdc42-overexpressing
(OE) mice) doxycycline (dox)-containing chow. To cre-
ate these mice the wild-type human Cdc42 cDNA was
inserted into a TetO-IRES-luciferase construct [14],
verified by sequencing, and tested for functionality
using MCF-7 Tet-On breast cancer cells [20] (Figure 1A
and data not shown). Pronuclear injection of the con-
struct yielded 42 potential founder mice, and screening
for the presence of the transgene by PCR led to the
identification of five positive lines. All five lines were
bred to the MMTV-rtTA mice, which express the rtTA
in the TEBs and ducts of the developing postnatal
mammary gland [16]. Beginning at 4.5 weeks of age,
TetO-Cdc42/MMTV-rtTA and MMTV-rtTA control
mice were fed either dox or non-dox-containing chow
to determine which lines were inducible as well as the
levels of Cdc42 overexpression. After 1 week, the mice
were euthanized, and mammary glands were dissected
for analysis. Whole mammary gland lysates were pre-
pared and luciferase assays were done to rapidly screen
for transgene expression. Four of the five founder lines
expressed the luciferase transgene at levels approxi-
mately 10 to 100 fold over controls in an inducible
fashion. Two of the lines, designated lines 3 and 4 (L3
and L4), were chosen for further analysis because they
expressed similar levels of luciferase activity (Figure 1B).
Western blot analysis of whole gland lysates showed that
Figure 1 Generation of the conditional Cdc42 overexpression mouse mammary gland model. (A) Schematic model of TetO-Cdc42/MMTV-
rtTA bigenic mice. The TetO-Cdc42 transgene contains the tetracycline operator and minimal cytomegalovirus (CMV) promoter with human
Cdc42 and IRES luciferase immediately downstream. TetO-Cdc42 mice were bred with the MMTV-rtTA mice to drive transgene expression in the
mammary gland [16]. In the presence of dox, rtTA activates expression of the Cdc42 transgene. Dox-treated MMTV-rtTA mice serve as controls for
all studies. (B) Graph depicts average luciferase levels of control (MMTV-rtTA, + dox) and lines 3 and 4 bigenic (TetO-Cdc42/MMTV-rtTA, -/+ dox)
mammary glands (n = 15,1,1,10,14). Transgene is induced only in bigenic mice treated with dox. (C) Western blot analysis of Cdc42 expression on
five pooled whole gland lysates per group after 3 weeks (Line 3) and 1 week (Line 4) of dox treatment. Densitometry values are normalized to
loading control and displayed as fold change compared to control. (D) Graph shows luciferase levels of mammary organoids and stromal cells
isolated from Cdc42 overexpressing and control mice (n = 3 animals pooled per group). Cdc42, cell division cycle 42; dox, doxycycline; MMTV-
rtTA, mouse mammary tumor virus reverse tetracycline transactivator; TetO, tetracycline operator.
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in both lines after 1 or 3 weeks of dox treatment compared
to dox-treated MMTV-rtTA control mice (Figure 1C).
To confirm that the transgene was confined to the epi-
thelial compartment, stromal cells and mammary organoids
were isolated from control and line 4 mammary glands
after 1 week of dox treatment. Our methods for stromal cell
isolation yield a relatively pure population with approxi-
mately 0.25% MEC contamination based on immunostain-
ing for markers of epithelial and stromal cells (data not
shown) [18]. Consistent with our analysis of whole mam-
mary gland lysates, a high level of luciferase activity was
detected in the mammary organoids from line 4 mice, but
not in control organoids or stromal cells from either con-
trol or Cdc42-overexpressing mammary glands (Figure 1D).
Combined, these data show that the Cdc42 transgene can
be inducibly overexpressed in the mammary glands of two
independent transgenic lines and that expression of the
transgene is restricted to the mammary epithelium.
Cdc42 overexpression in the developing mammary gland
induces abnormal TEBs and hyperbranching of the ductal
tree
We examined the effects of continuous Cdc42 over-
expression at early (5.5 weeks of age), middle (7.5 weeks
of age), and late (9 weeks of age) time points in thedeveloping postnatal mammary gland. Analysis of whole
mounted mammary glands at 5.5 and 7.5 weeks of age,
after 1 and 3 weeks of transgene expression, respectively,
revealed that Cdc42 overexpression induced abnormal
TEB morphologies characterized by hyperbudding and
trifurcation in both lines 3 and 4 (Figure 2A). The in-
creased presence of hyperbudded and trifurcated TEBs
suggested that long-term Cdc42 overexpression would
lead to increased branching of the ductal tree. Quantifi-
cation of branch points in whole mounted mammary
glands at 9 weeks of age, the developmental time point
when postnatal mammary gland development is typically
complete in the FVB/n strain of mice, showed a signifi-
cant increase in side branching in the mammary glands
of lines 3 and 4 as compared to mammary glands from
dox-treated control mice (Figure 2B). Additional defects
were noted in the Cdc42-overexpressing mammary
glands, including a mild reduction in total ductal tree
area, persistence of TEBs at the late developmental time
point, and regions of ductal dilation (Additional file 1).
The increased ductal branching was the most remark-
able phenotype present in the Cdc42-overexpressing
mammary glands, and we chose to pursue studies to de-
fine the mechanisms underlying this phenotype.
To begin to investigate the mechanisms that might be
contributing to the hyperbudded TEB and branching
Figure 2 Cdc42-overexpressing mammary glands display abnormal terminal end bud (TEB) morphologies and increased side branching.
(A) Representative images of wholemounted mammary glands from 1 week dox-treated line 3, line 4, and control mice. Scale bar = 1000 μm. Graph
depicts average number of abnormal TEBs (TEBs with multiple hyperbuds or trifurcations) per gland after 1 week or 3 weeks of dox treatment in lines
3 and 4 compared to dox-treated control mice (1 week n = 9,5,7 P = 0.01,0.07; 3 weeks n = 7,5,4 *P =<0.01). (B) Representative images of whole
mounted mammary glands from 5-week dox-treated mice. Scale bar = 1000 μm. Graph depicts average number of branch nodes after 5 weeks of
dox treatment in three 4 × 106 μm2 regions of the ductal tree on sides and leading edge of lymph node in number 4 mammary glands (line 3 n = 7,4
*P = 0.005; line 4 n = 8, *P = 0.001; control n = 7).
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was affecting apical and basal-lateral polarity establishment
or development of the myoepithelial and luminal cell com-
partments. Immunostaining to detect the apical surface
marker phosphorylated ezrin-radixin-moesin (pERM) and
the basal-lateral surface marker E-cadherin was done on
mammary gland tissue sections from dox-treated mice. No
differences were detected in the localization or intensity of
either marker within the TEBs or ducts, suggesting that
Cdc42 overexpression does not disrupt the establishment
of apical or basal-lateral polarity (Figure 3A-B). We also
performed immunostaining to detect the myoepithelial cell
marker keratin 14 (K14). K14-positive myoepithelial cells
localize to the neck region, whereas the K14-negative cap
cells localize to the middle and tip regions of the TEBs. We
noted that gaps in the K14-positive myoepithelial layer
were detectable at sites where branches were forming, and
gaps were more frequent in the Cdc42-overexpressingTEBs (Figure 3B). These results are consistent with pub-
lished studies showing that myoepithelial cells actively mi-
grate and partially cover growing branches [9], which are
more abundant in the Cdc42-overexpressing mammary
glands. Gaps in the myoepithelial layer were rarely detected
in fully formed ducts (Figure 3C). Collectively, these data
indicate that Cdc42 overexpression does not result in obvi-
ous defects in polarity establishment or development of
the myoepithelial and luminal compartments.
Cdc42 overexpression does not affect mammary
epithelial cell proliferation or survival rates
Branching of the mammary gland ductal tree is dependent
on cell proliferation [9], and we previously demonstrated
that Cdc42 is a crucial regulator of MEC proliferation [7].
We therefore hypothesized that Cdc42 overexpression
may increase proliferation rates to drive hyperbranching.
To investigate the effects of Cdc42 overexpression on
Figure 3 Cdc42-overexpressing mammary glands do not display defects in apical or basal-lateral polarity or development of the
myoepithelial or luminal cell compartments. (A) Representative images of TEBs from control and Cdc42-overexpressing mice immunostained
to detect the apical surface marker phosphorylated ERM (n = 5 animals per genotype with at least three TEBs analyzed per animal). Scale bars = 20 μm.
(B) Representative TEBs immunostained using antibodies against E-cadherin and keratin 14 to visualize the body and myoepithelial cell compartments,
respectively (n = 5 animals per genotype with at least three TEBs analyzed per animal). E-cadherin marks the surface of the body cells. Arrow indicates
gap in myoepithelial layer at a bud forming off a large TEB. Scale bars = 50 μm. (C) Representative images of mature ducts immunostained to detect
keratins 8 and 14 (n = 5 animals per genotype). Scale bars = 20 μm. Cdc42, cell division cycle 42; ERM, ezrin-radixin-moesin; TEB, terminal end bud.
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from 5.5- and 7.5-week-old dox-treated mice were im-
munostained for proliferation markers, including a mi-
tosis marker phosphorylated histone-H3 (pHH3), an
active cell cycle marker Ki67, and an S phase marker
bromodeoxyuridine (BrdU) incorporation (Figure 4A
and Additional file 2). Interestingly, quantification of
these markers did not reveal any differences in prolifer-
ation rates between Cdc42-overexpressing and control
TEBs or ducts at either time point. Immunostaining
and quantification of cleaved caspase 3 in the TEBs was
done to evaluate whether Cdc42 overexpression might
be increasing MEC survival, and again, no differences in
apoptosis rates were detected between the Cdc42-
overexpressing and control mammary glands (Figure 4B).
To further confirm these results the percentages of MECsin each phase of the cell cycle were analyzed by
performing flow cytometry on freshly isolated, PI-
stained MECs from mice treated for 1 week with dox
(Figure 4C). Indeed no differences in the cell cycle pro-
files were detected between the two groups. These re-
sults suggest that the hyperbudded TEBs and increased
side-branching phenotypes that were present in the
Cdc42-overexpressing mammary glands were not due
to defects in cell cycle progression of the MECs.
Cdc42 overexpression enhances MEC migration and
invasion
In addition to proliferation, cell migration is another
critical mechanism that contributes to mammary gland
branch formation [9]. Cell migration involves a multistep
process that requires both cell contraction and forward
Figure 4 MEC proliferation and survival rates are not altered in Cdc42-overexpressing mammary glands. (A) Representative images of pHH3
immunostaining on tissue sections from line 4 and control mammary glands treated for 1 week with dox. Scale bar = 50 μm. Graph shows average
percentage of pHH3-positive cells ± SEM in TEBs after 1 week and 3 weeks of dox treatment (n = 3,3;3,4, P = 0.43;0.77). (B) Representative images of
CC3 immunostaining on tissue sections from line 4 and control mammary glands treated for 1 week with dox. Scale bar = 50 μm. Graph depicts
average percentage of CC3-positive cells ± SEM in TEBs after 1 week and 3 weeks of dox treatment in vivo (n = 5,5;3,4 P = 0.53;0.59). (C) Histograms
represent flow cytometry analysis of isolated primary control and Cdc42-OE MECs stained with propidium iodide (PI) after 1 week of dox treatment
in vivo. Table shows the percentage of cells in each phase of the cell cycle out of total live cells (≥67,000 events) demonstrating that control and
Cdc42 OE MECs have similar cell cycle profiles. Data are representative of two independent experiments (n = 5 mice per genotype). CC3, cleaved
caspase-3; Cdc42, cell division cycle 42; MEC, mammary epithelial cell; OE, overexpressing; pHH3, phosphorylated histone-H3; TEB, terminal end bud.
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[21,22]. Because Cdc42 overexpression did not impact cell
cycle progression, we reasoned that the increased branching
could be due to enhanced cell migration. To investigate
this, we measured the ability of Cdc42-overexpressing
MECs to migrate using a transwell assay. Primary MECs
were serum starved, plated in serum-free medium in theupper chamber of the transwell, and serum-containing
medium was added to the bottom chamber to establish a
concentration gradient. The MECs were allowed to migrate
for 24 h and then fixed to prevent subsequent cell division.
Quantification of the number of migrated MECs showed
that Cdc42-overexpressing MECs were significantly more
migratory compared to control MECs (Figure 5A).
Figure 5 Cdc42 overexpression enhances MEC migration and contractility and development of dysmorphic, invasive mammary acini.
(A) Transwell migration assay analysis of primary MECs from line 4 and control mammary glands treated for 1 week with dox prior to isolation. Fold
change (± SEM) of total cells migrated was quantified per experiment. Data represent average of four independent experiments (n = 7 control
animals; n = 11 Cdc42 OE mice, *P = 0.005). (B) Western blot analysis of phosphorylated MLC on lysates prepared from whole mammary glands after
1 week of dox treatment (n = 5 animals pooled per group). Densitometry was normalized to actin loading control and is represented as fold increase
compared to control. (C) Graph depicts average area of collagen gel contraction (± SEM) at 24 and 48 h post release with and without the ROCK
inhibitor Y27632, (*P = 0.03). Data are representative of four independent experiments. (D) Three-dimensional culture morphogenesis assay of primary
MECs from 1-week dox-treated line 4 and control mammary glands. Representative confocal images depict control and abnormal Cdc42-
overexpressing acini. Arrows indicate invasive protrusions. Scale bar = 25 μm. (E) Graph depicts average fold change (± SEM) of total invasive acini per
well from three independent experiments (*P = 0.007). (F) Graph shows the average fold change in dysmorphic acini per well from three independent
experiments (*P = 0.008). (G) Analysis of mitotic spindle orientation in line 4 and control mammary acini (n = 50 spindles per genotype analyzed in
two independent experiments). Cdc42, cell division cycle 42; MEC, mammary epithelial cell; MLC, myosin light chain; OE, overexpressing.
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and we were interested in determining whether Cdc42-
overexpressing MECs were also more contractile. Western
blotting showed that phosphorylated myosin light
chain (MLC) was markedly upregulated in the Cdc42-
overexpressing mammary glands (Figure 5B). Next, weexamined the contractility of the Cdc42-overexpressing
MECs using a collagen gel contractility assay in which
MECs were plated in a collagen gel and the gel was re-
leased from the plate after 48 h. At the time of release, the
cultures were treated with the ROCK inhibitor Y27632,
which is activated by Rho GTPases and regulates MLC-
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area after 24 and 48 h showed that the Cdc42-
overexpressing MECs were significantly more contractile
than control MECs and that ROCK inhibition blocked
MEC contractility, confirming the importance of Rho
GTPase-mediated actomyosin contractility in this process
(Figure 5C).
The increased contractility and motility of the Cdc42-
overexpressing MECs suggested that they would also be
more invasive. We therefore investigated whether Cdc42
overexpression would promote invasion of MECs under-
going morphogenesis in three-dimensional Matrigel cul-
tures. Single MECs were seeded in Matrigel, and after 6
days the cultures were stained with fluorescent-tagged
phalloidin and analyzed using confocal microscopy.
Cdc42 overexpression resulted in a significant increase
in the number of invasive acini, which were defined as
acini with an invasive protrusion or at least one cell mi-
grating away from the acinus (Figure 5D-E). A signifi-
cant increase in the presence of dysmorphic acini, which
were defined as elongated, flattened, or nonspherical
acini, was also detected in the Cdc42-overexpressing cul-
tures (Figure 5D-F). These data are consistent with our
in vivo results demonstrating aberrant TEB morpholo-
gies and increased branching in Cdc42-overexpressing
mammary glands.
Cdc42 affects epithelial organization in part through
regulation of mitotic spindle orientation [24]. We con-
sidered the possibility that Cdc42 overexpression might
be altering spindle orientation to promote the formation
of dysmorphic and invasive acini. To investigate this,
Cdc42 overexpressing and control acini were stained
with α-tubulin and α6-integrin to visualize the mitotic
spindles and basal surface of the acini, respectively. Spin-
dle orientation was scored as parallel, perpendicular, or
angled with respect to the basal surface. This analysis
showed that Cdc42 overexpression does not alter spindle
orientation in developing acini (Figure 5G), suggesting
that spindle orientation defects do not contribute to the
formation of the abnormal Cdc42-overexpressing acini.
Elevated Rho GTPase activity and downstream activa-
tion of MAPK signaling has been shown to increase MEC
contractility, disrupt MEC morphogenesis, and promote
invasion [25,26]. To determine whether deregulated Rho
GTPase activity and MAPK signaling might contribute to
the Cdc42 overexpression phenotypes, we investigated the
effects of Cdc42 overexpression on Rho GTPase activity
in the developing mammary epithelium. Organoids were
isolated from 1- and 3-week dox-treated mice, and Cdc42,
RhoA, and Rac activities were quantified using GLISA as-
says. Interestingly, a small, but significant increase in
RhoA activity was detected after 1 week of dox treatment
in Cdc42-overexpressing MECs relative to control MECs
(Figure 6A). In contrast, Cdc42 activity was not alteredat this time point. After 3 weeks of dox treatment, however,
Cdc42 activity was significantly increased in Cdc42-
overexpressing MECs compared to control MECs, whereas
RhoA activity was no longer elevated (Figure 6A-B). No
changes in Rac activity levels were detected at either time
point (Figure 6C). To determine if MAPK signaling was
also altered in the Cdc42-overexpressing mammary glands
we performed western blotting for phosphorylated MAPK
proteins on mammary gland lysates prepared from lines 3
and 4 and control mice, which showed a marked increase
in phosphorylated extracellular signal-related kinase (ERK),
p38, and c-Jun N-terminal kinase (JNK) (Figure 6D). These
data indicate that Cdc42 overexpression results in dynamic
regulation of RhoA and Cdc42 activities and increased
MAPK activity in the developing mammary epithelium,
which likely contribute to the Cdc42 overexpression-
mediated MEC phenotypes in vitro and in vivo.
Cdc42-overexpressing mammary glands exhibit features
associated with stromal activation
Crosstalk between the epithelial and stromal compart-
ments is known to play an important role in normal and
neoplastic mammary gland development. More specific-
ally, extracellular matrix (ECM) deposition and remodel-
ing by stromal cells contributes to mammary gland
branching morphogenesis and patterning of the ductal
tree [27], and aberrant ECM deposition and remodeling
disrupts MEC morphogenesis and facilitates invasion
[25,26,28,29]. Previously, we reported that abnormal
TEB morphogenesis and hyperbranching of the ductal
tree occurred in p190B RhoGAP-overexpressing mice in
association with increased ECM deposition [17]. We
were therefore interested in determining if ECM depos-
ition was altered in the mammary glands of the Cdc42-
overexpressing mice. First, we measured the thickness of
the stroma in the neck region adjacent to the TEBs in
H&E-stained tissue sections. This analysis demonstrated
that the stroma associated with the Cdc42-overexpressing
TEBs was significantly thicker in comparison to control
TEBs (Figure 7A). To determine if expansion of the stro-
mal cell population contributed to the increased stromal
thickness, cell proliferation in the stroma adjacent to the
TEBs was quantified using Ki67 staining. However, no dif-
ferences in proliferation rates were detected, suggesting
that expansion of the stromal population did not ac-
count for the increased ECM deposition (data not
shown). We also performed F4/80 immunostaining to
analyze macrophage infiltration, which is important for
TEB and branching morphogenesis [30]. Furthermore,
increased macrophage infiltration has been shown to
promote mammary gland hyperbranching [31]. Quanti-
fication of F4/80+ cells did not reveal any differences in
the number of infiltrating macrophages associated with
the Cdc42 overexpressing compared to control TEBs
Figure 6 Cdc42 and RhoA activities and MAPK signaling are upregulated in Cdc42-overexpressing mammary glands. (A) Graph depicts
RhoA activity as average light units (ALU) (± SEM) in lysates prepared from mammary organoids isolated from line 4 and control mice after 1 week
and 3 weeks of dox treatment (*P = 0.02). Data represent four animals at 1 week and two animals at 3 weeks per group. (B) Graph shows Cdc42
activity as average OD 490 readings (± SEM) from lysates prepared from organoids isolated from line 4 and control mice after 1 week and 3 weeks of
dox treatment (*P = 0.01). Data represent four animals per group at 1 week and three animals per group at 3 weeks. (C) Rac activity assay
results are representative of three animals per group at 1 week and five animals per group at 3 weeks. (D) Western analysis of phosphorylated
ERK, P38, and JNK in lysates prepared from whole mammary glands after 3 weeks of dox treatment (n = 5 pooled animals per group). Densitometry
values are normalized to tubulin loading control and represented as fold change compared to control. Cdc42, cell division cycle 42; ERK, extracellular
signal-related kinase; JNK, c-Jun N-terminal kinase; MAPK, mitogen-activated protein kinase; Rho, Ras homolog gene family, member A.
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to determine whether changes in the activation status
of the macrophage population contribute to the Cdc42-
overexpressing mammary gland phenotypes.
To evaluate the composition of the thickened ECM, tis-
sue sections were stained with Masson’s trichrome, and
collagen accumulation in the stroma adjacent to the TEBs
was quantified. These data show that increased collagen
deposition contributed to the stromal thickness surround-
ing the Cdc42-overexpressing TEBs (Figure 7C). To
further investigate the stromal changes, we performed
qRT-PCR Super Array analysis for adhesion and ECM
genes on cDNA prepared from freshly isolated stromalcells and found that mRNA expression levels for several in-
tegrin, collagen, and matrix metalloprotease (MMP) family
members were upregulated greater than 1.5 fold in the stro-
mal cells from Cdc42-overexpressing compared to control
mammary glands (Figure 7D). qRT-PCR using additional
primer sets was done to validate five of these genes, which
confirmed that mRNA expression levels of type I collagen,
fibronectin, MMP-2, MMP-3, and MMP-9 were elevated in
the stromal cells from Cdc42-overexpressing mammary
glands (Figure 7E). Collectively, these data suggest that
overexpression of Cdc42 in the mammary epithelium alters
epithelial-stromal interactions, leading to increased ECM
deposition and potentially ECM remodeling.
Figure 7 (See legend on next page.)
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Figure 7 Cdc42-overexpressing mammary glands display characteristics associated with stromal activation. (A) Representative images of
H&E-stained longitudinally sectioned TEBs from 1 week dox-treated Cdc42-overexpressing and control mammary glands. Scale bar = 100 μm.
Graph depicts average stromal thickness (± SEM) at neck region of TEBs (n = 7,5; *P = 0.008). (B) Representative images of F4/80-immunostained
TEBs from 1 week dox-treated Cdc42-overexpressing and control mammary glands (n = 4 to 5 animals per genotype, with at least three TEBs
analyzed per mouse). Scale bar = 50 μm. Graph shows percentage of F4/80-positive stromal cells (± SEM). (C) Representative images of Masson’s
trichrome-stained TEBs (blue) (n = 4 animals per genotype, with an average of three TEBs analyzed per mouse). Scale bar = 50 μm. Graph depicts
quantification of collagen deposition (*P= 0.009). (D) Table of qRT-PCR Super Array results showing genes that were upregulated at least 1.5 fold in
stromal cells isolated from Cdc42-overexpressing compared to control mammary glands. Data are representative of three animals per genotype.
(E) qRT-PCR and new primer sets were used to validate several genes identified in the Super Array. Graph shows fold change in mRNA expression
levels (*P = 0.0003, **P = 0.04, ***P = 0.003, #P = 0.001, ##P = 0.005). Data are representative of three animals per group. Cdc42, cell division cycle 42;
TEB, terminal end bud.
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Cdc42 is overexpressed and hyperactivated in human
breast tumors [2,3]. However, the effects of Cdc42
overexpression on mammary gland development and the
stochastic process of tumor formation in vivo have not
been previously investigated due to a lack of Cdc42-
overexpressing mouse models. Here we describe the
generation of a novel conditional Cdc42-overexpressing
mouse model and the effects of Cdc42 overexpression
during postnatal mammary gland development. We
show that overexpression of Cdc42 disrupts TEB mor-
phogenesis and promotes hyperbranching of the ductal
tree in association with stromal alterations. Furthermore,
our data suggest that increased MEC contractility and
migration, potentially via upregulation of MAPK signal-
ing, contributes to these phenotypes.
Although Cdc42 is overexpressed and hyperactivated
in breast tumors [2,3], mutations in Cdc42 have not
been found [32]. Thus, regulation of Cdc42 protein
translation, stability, and GTP hydrolysis and exchange
rates likely underlie Cdc42’s altered expression and ac-
tivity in tumors. When we designed the TetO-Cdc42
model, we aimed to accurately recapitulate this regula-
tion, and therefore, chose to overexpress wild-type
Cdc42 rather than a constitutively active mutant. Using
this approach, we showed that Cdc42 and RhoA activ-
ities are differentially elevated in the mammary epithe-
lium of the Cdc42-overexpressing mice during the
developmental time course that we examined.
Cdc42 is upregulated early in MECs undergoing mor-
phogenesis [33], and it is essential for polarity establish-
ment and proliferation during the early stages of MEC
morphogenesis [7,34,35]. These studies together with
our data demonstrating that Cdc42 overexpression dis-
rupts MEC acinus morphology in three-dimensional cul-
tures and TEB architecture in vivo, suggest that precise
regulation of Cdc42 activity is important for proper
MEC morphogenesis and branching. Normal MECs
likely have multiple mechanisms to ensure that proper
levels of Cdc42 activity are maintained. One potential
mechanism could involve RhoGDI1, which functions to
sequester and maintain Rho GTPases in their inactivestate in the cytoplasm [36]. Levels of RhoGDI1 are lim-
ited, and overexpression of one Rho GTPase can dis-
place another family member, resulting in increased
activation of the displaced family member [37]. This
mechanism could account for the absence of elevated
Cdc42 activity and concomitant increase in RhoA that
we observed at the early developmental time. At the
mid-developmental time point after the early stages of
MEC morphogenesis and initiation of branching are
complete, precise control of Cdc42 activity may no lon-
ger be crucial and elevated Cdc42 activity may facilitate
branch elongation by enhancing MEC migration and in-
vasion. Increased stromal deposition affects Rho GTPase
activity in MECs [26,38], and it is possible that the stro-
mal alterations detected in the Cdc42-overexpressing
mammary glands also impact RhoA and Cdc42 activa-
tion. Further studies will be required to define the mech-
anisms regulating Rho GTPase activity in normal and
transformed MECs.
It is interesting to note that overexpression of Cdc42
and p190B RhoGAP in the developing postnatal mam-
mary gland have similar phenotypes, including abnormal
TEBs, hyperbranching, and increased stromal deposition
[17]. Similar to the Cdc42-overexpressing MECs, p190B-
overexpressing MECs also display increased contractility
[18]. Thus, disruption of the Rho signaling network in
MECs, leading to increased intracellular contractility may
play an important role in driving these phenotypes. In-
deed, actomyosin-mediated contractility regulates mam-
mary organoid branching in vitro [9].
One distinction between the p190B- and Cdc42-
overexpressing mammary gland phenotypes is that p190B-
overexpressing MECs exhibited both increased migration
and proliferation [17,39], whereas Cdc42-overexpressing
MECs displayed only increased migration. We anticipated
that Cdc42 overexpression might enhance proliferation as
our published studies investigating the effects of Cdc42
knockout during primary MEC morphogenesis in vitro
demonstrated that Cdc42 is a critical regulator of MEC
proliferation [7]. Furthermore, mammary gland branching
is driven by both MEC proliferation and migration [9].
However, our studies suggest that Cdc42 overexpression
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ing increased MEC contractility and migration in the ab-
sence of any effects on proliferation.
The promigratory effects of Cdc42 overexpression in
MECs are supported by the literature describing other
Cdc42 gain of function models. A migration phenotype
was reported in mouse embryonic fibroblasts isolated
from Cdc42GAP knockout mice in which elevated
Cdc42 activity disrupted directional migration [40]. In
addition, neutrophils isolated from the Cdc42GAP
knockout mice had an increased ability to migrate, but
the direction of migration was disrupted [41]. Interest-
ingly, MAPK signaling contributed to the migration
phenotype in the Cdc42GAP knockout neutrophils,
which showed changes in ERK and p38 phosphorylation
that were similar to those detected in the Cdc42-
overexpressing mammary glands. MAP kinases, includ-
ing ERK, p38, and JNK, have been broadly implicated as
regulators of cell proliferation and migration in diverse
cell types in response to a variety of stimuli [42-44]. Our
detailed analysis of cell cycle progression and apoptosis in
the Cdc42-overexpressing mammary glands did not reveal
any alterations in cell proliferation or survival. Thus, ele-
vated MAPK activity in the Cdc42-overexpressing mam-
mary glands may regulate MEC migration and invasion to
promote hyperbranching.
Disruption of epithelial architecture is an important
hallmark of breast cancer initiation, it contributes to in-
vasion and metastasis, and it can be used to help predict
survival [45-48]. The abnormal TEB morphologies
detected in the Cdc42-overexpressing mammary glands
together with our reported loss-of-function studies dem-
onstrating the requirement for Cdc42 during the early
stages of MEC acinus formation [7], suggest that Cdc42
is a key regulator of mammary epithelial architecture.
Thus, Cdc42 overexpression may cooperate with initiating
oncogenes to facilitate the disruption of epithelial archi-
tecture during the early stages of tumorigenesis. The
increased migratory and invasive capacity of the Cdc42-
overexpressing MECs suggests that Cdc42 overexpression
may facilitate mammary tumor cell invasion and metasta-
sis in vivo, and indeed, studies investigating the effects of
Cdc42 knockdown in breast cancer xenografts have
shown that Cdc42 regulates tumor cell invasion and me-
tastasis in vivo [49]. Furthermore, an intriguing possibility
is that Cdc42 overexpression may function during the
early stages of tumor formation to induce protumorigenic
and proinvasive stromal alterations. Future studies will be
aimed at using this novel mouse model to determine
the contribution of Cdc42 during different stages of
tumor formation and progression and to define the mo-
lecular mechanisms by which aberrant Cdc42 expres-
sion facilitates these processes. A better understanding
of how Cdc42 overexpression impacts the developmentand progression of breast cancer will help to pinpoint
when targeting Cdc42 would be most effective and will
define how best to target its aberrant actions.
Conclusions
Overexpression of Cdc42 in the developing mammary gland
induces aberrant TEB morphogenesis and hyperbranching
of the ductal tree in association with stromal alter-
ations. Elevated MAPK signaling leading to increased
MEC contractility and migration likely contributes to
the Cdc42-overexpressing mammary gland morpho-
genetic defects. This novel mouse model will serve as
an important tool to define the cellular and molecular
mechanisms by which Cdc42 overexpression affects
mammary tumor formation, progression, and metasta-
sis in vivo.
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Additional file 1: (A) Whole mount mammary gland images and
quantification of average number of terminal end buds (TEBs) in
animals with TEBs (≥100 μm diameter) (± SEM) in 5-week dox-treated
whole mounts (n = 8,9; *P = 0.03). (B) Whole mount mammary gland
images and average number of dilated regions (± SEM) per whole mount
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*P <0.02). (C) Whole mount images and average ductal tree area (± SEM) of
5-week dox-treated animals (n = 8,9; *P <0.02).
Additional file 2: (A) Average percentage of Ki67-positive cells
(± SEM) in terminal end buds (TEBs) after 1 week and 3 weeks of
dox treatment in vivo (n = 9,8;3,4 *P = 0.34;0.88). (B) Average
percentage of BrdU-positive cells (± SEM) in TEBs after 3 weeks of dox
treatment in vivo (n = 3,4; *P = 0.23). BrdU, 5-bromo-2-deoxyuridine.
Abbreviations
BCA: Bicinchoninic acid assay; BrdU: 5-bromo-2-deoxyuridine; BSA: Bovine
serum albumin; Cdc42: Cell division cycle 42; DMEM/F-12: Dulbecco’s modified
Eagle’s medium nutrient mixture F-12; dox: Doxycycline; ECM: Extracellular
matrix; ERK: Extracellular signal-related kinase; GAP: GTPase-activating protein;
GEF: Guanine nucleotide exchange factor; GTPase: Guanine nucleotide
triphophatase; IF: Immunofluorescence; IHC: Immunohistochemistry; JNK: c-Jun
N-terminal kinase; L3: Transgenic founder line number 3; L4: Transgenic founder
line number 4; MAPK: Mitogen-activated protein kinase; MEC: Mammary
epithelial cell; MEGM: Mammary epithelial cell growth medium; MLC: Myosin
light chain; MMP: Matrix metalloprotease; MMTV-rtTA: Mouse mammary tumor
virus reverse tetracycline transactivator; OE: Overexpression; PBS: Phosphate-
buffered saline; PI: Propidium iodide; qRT-PCR: Quantitative reverse-transcription
polymerase chain reaction; Rac: Ras-related C3 botulinum toxin substrate 1;
RhoA: Ras homolog gene family, member A; ROCK: Rho-associated coiled-coil
containing protein kinase; TEB: Terminal end bud; TetO: Tetracycline operator.
Competing interests
The authors declare no competing interests.
Authors’ contributions
KB designed and performed experiments and analyzed data, including
analysis of Cdc42 expression and signaling, mammary gland phenotypes,
immunostaining, and three-dimensional culture experiments. KB also helped
draft the manuscript. MG performed contraction assays, immunostaining,
q-RT-PCR, and analyzed data. JY performed migration assays, GLISA assays,
spindle analysis, analyzed mammary gland phenotypes, and analyzed and
interpreted results. EL performed and analyzed immunostaining on tissue
sections. MH and JCS generated and tested the construct to make the TetO-
Cdc42-overexpressing mice. MH performed initial characterization to identify
inducible Cdc42-overexpressing transgenic lines. TVG conceived of the study
Bray et al. Breast Cancer Research 2013, 15:R91 Page 17 of 18
http://breast-cancer-research.com/content/15/5/R91and designed and directed the experiments, analyzed data, and drafted the
manuscript. All authors have read and approved the final manuscript.Acknowledgements
Funding for these studies was provided in part by an Indiana University
School of Medicine Research Support Funds grant and a National Institutes
of Health Clinical Translational Sciences Institute grant RR025761. We would
like to thank Charles Tessier, director of the CTSI IUSM-SB Imaging and Flow
Cytometry Core Facility, for his help with the flow cytometry and confocal
microscopy experiments. We would also like to acknowledge the Transgenic
and Knockout Mouse Core facility at the Indiana University School of
Medicine for assistance with generating the transgenic founder lines. We
would also like to thank Lindsay Nowak for technical support.
Received: 12 April 2013 Accepted: 16 September 2013
Published: 30 September 2013References
1. Ellenbroek SI, Collard JG: Rho GTPases: functions and association with
cancer. Clin Exp Metastasis 2007, 24:657–672.
2. Fritz G, Just I, Kaina B: Rho GTPases are over-expressed in human tumors.
Int J Cancer 1999, 81:682–687.
3. Fritz G, Brachetti C, Bahlmann F, Schmidt M, Kaina B: Rho GTPases in
human breast tumours: expression and mutation analyses and
correlation with clinical parameters. Br J Cancer 2002, 87:635–644.
4. Stengel K, Zheng Y: Cdc42 in oncogenic transformation, invasion, and
tumorigenesis. Cellular Signal 2011, 23:1415–1423.
5. Pedersen E, Brakebusch C: Rho GTPase function in development: how
in vivo models change our view. Exp Cell Res 2012, 318:1779–1787.
6. Heasman SJ, Ridley AJ: Mammalian Rho GTPases: new insights into their
functions from in vivo studies. Nat Rev 2008, 9:690–701.
7. Bray K, Brakebusch C, Vargo-Gogola T: The Rho GTPase Cdc42 is required
for mammary epithelial cell morphogenesis in vitro. Small GTPases 2011,
2:247–258.
8. Hennighausen L, Robinson GW: Signaling pathways in mammary gland
development. Dev Cell 2001, 1:467–475.
9. Ewald AJ, Brenot A, Duong M, Chan BS, Werb Z: Collective epithelial
migration and cell rearrangements drive mammary branching
morphogenesis. Dev Cell 2008, 14:570–581.
10. Nguyen-Ngoc KV, Cheung KJ, Brenot A, Shamir ER, Gray RS, Hines WC,
Yaswen P, Werb Z, Ewald AJ: ECM microenvironment regulates collective
migration and local dissemination in normal and malignant mammary
epithelium. Proc Natl Acad Sci U S A 2012, 109:E2595–E2604.
11. Nelson CM, Gleghorn JP: Sculpting organs: mechanical regulation of
tissue development. Annu Rev Biomed Eng 2012, 14:129–154.
12. Hall A: Rho family GTPases. Biochem Soc Trans 2012, 40:1378–1382.
13. Zhu W, Nelson CM: PI3K regulates branch initiation and extension of
cultured mammary epithelia via Akt and Rac1 respectively. Dev Biol 2013,
379:235–245.
14. Gunther EJ, Moody SE, Belka GK, Hahn KT, Innocent N, Dugan KD, Cardiff
RD, Chodosh LA: Impact of p53 loss on reversal and recurrence of
conditional Wnt-induced tumorigenesis. Genes Dev 2003, 17:488–501.
15. Oesterreich S, Zhang P, Guler RL, Sun X, Curran EM, Welshons WV, Osborne
CK, Lee AV: Re-expression of estrogen receptor alpha in estrogen
receptor alpha- negative MCF-7 cells restores both estrogen and insulin-
like growth factor-mediated signaling and growth. Cancer Res 2001,
61:5771–5777.
16. Gunther EJ, Belka GK, Wertheim GB, Wang J, Hartman JL, Boxer RB, Chodosh
LA: A novel doxycycline-inducible system for the transgenic analysis of
mammary gland biology. FASEB J Mar 2002, 16:283–292.
17. Vargo-Gogola T, Heckman BM, Gunther EJ, Chodosh LA, Rosen JM: P190-B
Rho GTPase-activating protein overexpression disrupts ductal
morphogenesis and induces hyperplastic lesions in the developing
mammary gland. Mol Endocrinol 2006, 20:1391–1405.
18. Gillette M, Bray K, Blumenthaler A, Vargo-Gogola T: P190B RhoGAP
overexpression in the developing mammary epithelium induces
TGFbeta-dependent fibroblast activation. PLoS One 2013, 8:e65105.
19. Debnath J, Muthuswamy SK, Brugge JS: Morphogenesis and oncogenesis
of MCF-10A mammary epithelial acini grown in three-dimensional
basement membrane cultures. Methods 2003, 30:256–268.20. Fowler AM, Solodin N, Preisler-Mashek MT, Zhang P, Lee AV, Alarid ET:
Increases in estrogen receptor-alpha concentration in breast cancer cells
promote serine 118/104/106-independent AF-1 transactivation and
growth in the absence of estrogen. FASEB J 2004, 18:81–93.
21. Nobes CD, Hall A: Rho GTPases control polarity, protrusion, and adhesion
during cell movement. J Cell Biol 1999, 144:1235–1244.
22. Ridley AJ: Life at the leading edge. Cell 2011, 145:1012–1022.
23. Wilkinson S, Paterson HF, Marshall CJ: Cdc42-MRCK and Rho-ROCK
signalling cooperate in myosin phosphorylation and cell invasion.
Nat Cell Biol 2005, 7:255–261.
24. Jaffe AB, Kaji N, Durgan J, Hall A: Cdc42 controls spindle orientation to
position the apical surface during epithelial morphogenesis. J Cell Biol
2008, 183:625–633.
25. Paszek MJ, Zahir N, Johnson KR, Lakins JN, Rozenberg GI, Gefen A, Reinhart-
King CA, Margulies SS, Dembo M, Boettiger D, Hammer DA, Weaver VM:
Tensional homeostasis and the malignant phenotype. Cancer Cell 2005,
8:241–254.
26. Provenzano PP, Inman DR, Eliceiri KW, Keely PJ: Matrix density-induced
mechanoregulation of breast cell phenotype, signaling and gene
expression through a FAK-ERK linkage. Oncogene 2009, 28:4326–4343.
27. Schedin P, Keely PJ: Mammary gland ECM remodeling, stiffness, and
mechanosignaling in normal development and tumor progression.
Cold Spring Harb Perspect Biol 2011, 3:a003228.
28. Provenzano PP, Eliceiri KW, Campbell JM, Inman DR, White JG, Keely PJ:
Collagen reorganization at the tumor-stromal interface facilitates local
invasion. BMC Med 2006, 4:38.
29. Levental KR, Yu H, Kass L, Lakins JN, Egeblad M, Erler JT, Fong SF, Csiszar K,
Giaccia A, Weninger W, Yamauchi M, Gasser DL, Weaver VM: Matrix
crosslinking forces tumor progression by enhancing integrin signaling.
Cell 2009, 139:891–906.
30. Gouon-Evans V, Rothenberg ME, Pollard JW: Postnatal mammary gland
development requires macrophages and eosinophils. Development 2000,
127:2269–2282.
31. Schwertfeger KL, Xian W, Kaplan AM, Burnett SH, Cohen DA, Rosen JM:
A critical role for the inflammatory response in a mouse model of
preneoplastic progression. Cancer Res 2006, 66:5676–5685.
32. Rihet S, Vielh P, Camonis J, Goud B, Chevillard S, de Gunzburg J: Mutation
status of genes encoding RhoA, Rac1, and Cdc42 GTPases in a panel of
invasive human colorectal and breast tumors. J Cancer Res Clin Oncol
2001, 127:733–738.
33. Whyte J, Thornton L, McNally S, McCarthy S, Lanigan F, Gallagher WM, Stein T,
Martin F: PKCzeta regulates cell polarisation and proliferation restriction
during mammary acinus formation. J Cell Sci 2010, 123:3316–3328.
34. Akhtar N, Streuli CH: Rac1 links integrin-mediated adhesion to the control
of lactational differentiation in mammary epithelia. J Cell Biol 2006,
173:781–793.
35. Duan L, Chen G, Virmani S, Ying G, Raja SM, Chung BM, Rainey MA, Dimri M,
Ortega-Cava CF, Zhao X, Clubb RJ, Tu C, Reddi AL, Naramura M, Band V,
Band H: Distinct roles for Rho versus Rac/Cdc42 GTPases downstream of
Vav2 in regulating mammary epithelial acinar architecture. J Biol Chem
2010, 285:1555–1568.
36. Garcia-Mata R, Boulter E, Burridge K: The ‘invisible hand’: regulation of
RHO GTPases by RHOGDIs. Nat Rev Mol Cell Biol 2011, 12:493–504.
37. Boulter E, Garcia-Mata R, Guilluy C, Dubash A, Rossi G, Brennwald PJ,
Burridge K: Regulation of Rho GTPase crosstalk, degradation and activity
by RhoGDI1. Nat Cell Biol 2010, 12:477–483.
38. Paszek MJ, Weaver VM: The tension mounts: mechanics meets
morphogenesis and malignancy. J Mammary Gland Biol Neoplasia 2004,
9:325–342.
39. McHenry PR, Sears JC, Herrick MP, Chang P, Heckman-Stoddard BM,
Rybarczyk M, Chodosh LA, Gunther EJ, Hilsenbeck SG, Rosen JM, Vargo-
Gogola T: P190B RhoGAP has pro-tumorigenic functions during MMTV-
Neu mammary tumorigenesis and metastasis. Breast Cancer Res 2010,
12:R73.
40. Yang L, Wang L, Zheng Y: Gene targeting of Cdc42 and Cdc42GAP
affirms the critical involvement of Cdc42 in filopodia induction, directed
migration, and proliferation in primary mouse embryonic fibroblasts. Mol
Biol Cell 2006, 17:4675–4685.
41. Szczur K, Xu H, Atkinson S, Zheng Y, Filippi MD: Rho GTPase CDC42
regulates directionality and random movement via distinct MAPK
pathways in neutrophils. Blood 2006, 108:4205–4213.
Bray et al. Breast Cancer Research 2013, 15:R91 Page 18 of 18
http://breast-cancer-research.com/content/15/5/R9142. Huang C, Jacobson K, Schaller MD: MAP kinases and cell migration. J Cell
Sci 2004, 117:4619–4628.
43. Wagner EF, Nebreda AR: Signal integration by JNK and p38 MAPK
pathways in cancer development. Nat Rev Cancer 2009, 9:537–549.
44. Whyte J, Bergin O, Bianchi A, McNally S, Martin F: Key signalling nodes in
mammary gland development and cancer. Mitogen-activated protein
kinase signalling in experimental models of breast cancer progression
and in mammary gland development. Breast Cancer Res 2009, 11:209.
45. Muthuswamy SK, Xue B: Cell polarity as a regulator of cancer cell
behavior plasticity. Ann Rev Cell Dev Biol 2012, 28:599–625.
46. Hanahan D, Weinberg RA: The hallmarks of cancer. Cell 2000, 100:57–70.
47. Hanahan D, Weinberg RA: Hallmarks of cancer: the next generation.
Cell 2011, 144:646–674.
48. Tambasco M, Eliasziw M, Magliocco AM: Morphologic complexity of
epithelial architecture for predicting invasive breast cancer survival.
J Transl Med 2011, 8:140.
49. Bouzahzah B, Albanese C, Ahmed F, Pixley F, Lisanti MP, Segall JD,
Condeelis J, Joyce D, Minden A, Der CJ, Chan A, Symons M, Pestell RG:
Rho family GTPases regulate mammary epithelium cell growth and
metastasis through distinguishable pathways. Mol Med 2001, 7:816–830.
doi:10.1186/bcr3487
Cite this article as: Bray et al.: Cdc42 overexpression induces
hyperbranching in the developing mammary gland by enhancing cell
migration. Breast Cancer Research 2013 15:R91.Submit your next manuscript to BioMed Central
and take full advantage of: 
• Convenient online submission
• Thorough peer review
• No space constraints or color ﬁgure charges
• Immediate publication on acceptance
• Inclusion in PubMed, CAS, Scopus and Google Scholar
• Research which is freely available for redistribution
Submit your manuscript at 
www.biomedcentral.com/submit
